• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Osteoporosis medications may improve bone health in men receiving androgen deprivation therapy for prostate cancer

byEvelyn NguyenandDeepti Shroff Karhade
August 10, 2017
in Chronic Disease, Endocrinology, Imaging and Intervention, Oncology, Surgery, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Bisphosphonates and denosumab increased bone mineral density (BMD) in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer, with denosumab also showing some evidence of vertebral fracture reduction.

2. Three trials for lifestyle intervention showed no statistically significant difference in BMD compared to exercise and standard care.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nearly half of men with prostate cancer receive ADT sometime after diagnosis. Some of the risks of ADT include bone loss and higher risk of low trauma fractures. Considering that most men with prostate cancer are elderly and already at risk of osteoporosis, the risks of ADT therapy are even more important. This systematic review sought to evaluate drug, supplement, and lifestyle interventions for their effectiveness in improving BMD, preventing fracture, or preventing or delaying osteoporosis in males with nonmetastic prostate cancer. Bisphosphonates improved BMD, but there were no trials with sufficient power to detect fracture reduction. Denosumab increased BMD, and one high-quality trial showed that denosumab decreased the incidence of vertebral fractures. Three trials for lifestyle intervention showed no statistically significant difference in BMD compared to exercise and standard care. For men receiving ADT for nonmetastatic prostate cancer, bisphosphonates or denosumab may improve BMD. Additional trials evaluating fracture outcomes in this population are needed.

A strength of the study is that rigorous methodologies were used to assess both pharmacologic and nonpharmacologic treatment trials. In addition, updated meta-analysis and sensitivity analyses were used for evidence summary. Limitations of the study include the lack of randomized controlled trials (RCTs) examining fracture outcomes, trials being mainly of moderate quality, and the lack of evaluation of potential treatment harms.

Click to read the study, published in Annals of Internal Medicine

RELATED REPORTS

Exercise improves sexual function in men with prostate cancer  

Genome classifiers may aid prostate cancer risk stratification and treatment

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

Relevant Reading: Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care — cancer care Ontario clinical practice guideline

In-Depth [systematic review and meta-analysis]: Using data from Ovid MEDLINE (1946 to 19 January 2017), EMBASE (1980 to 18 January 2017), and Cochrane Database of Systematic Reviews (19 January 2017), researchers from McMaster University evaluated two systematic reviews and 28 reports (of 27 trials) that focused on males receiving ADT for nonmetastatic prostate cancer. RCTs or systematic reviews pertaining to therapies aimed at bone health improvement were analyzed. Bisphosphonates improved BMD, with evidence suggesting that intravenous forms of the drug may have higher effectiveness than oral forms. Denosumab (60 mg administered subcutaneously every 6 months) also improved BMD and reduced the occurrence of new vertebral fractures detected on radiographs. Toremifene also reduced fracture incidence, but it is not approved by the U.S. Food and Drug Administration for this purpose.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bisphosphonatesdenosumabprostate cancer
Previous Post

HCV treatment administered by nonspecialist providers as safe and effective as that provided by specialists

Next Post

Plasma Epstein–Barr virus DNA useful for nasopharyngeal carcinoma screening

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Exercise improves sexual function in men with prostate cancer  

May 24, 2025
BRAF V600E mutations linked with increased mortality in thyroid cancer
Oncology

Genome classifiers may aid prostate cancer risk stratification and treatment

January 20, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Androgen deprivation in prostate cancer: intermittent may compromise survival
Chronic Disease

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

December 18, 2024
Next Post
Diacylglycerol kinase α is a potential target for X-linked lymphoproliferative disease treatment [PreClinical]

Plasma Epstein–Barr virus DNA useful for nasopharyngeal carcinoma screening

Delays in surgical intervention do not increase odds of appendiceal perforation

Cerebral embolic protection devices not effective in surgical aortic valve repair

Long-term outcomes for off-pump and on-pump CABG are similar

Levosimendan not effective in reducing postoperative low cardiac output syndrome in select heart surgery patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair
  • #VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.